Cereno Scientific identifies possibilities for expanding the use of its treatment concept in cardiovascular diseases
(WorldNews Sweden)

24 May, 2019 Through its Scientific Advisory Board, Cereno Scientific has identified the potential for the company`s treatment concept for cardiovascular diseases to inhibit, or even regulate, the progression of fibrosis. Fibrosis is a fundamental mechanism for the progress of several cardiovascular diseases. The company can thus expand the field of indication for its treatment concept with its drug candidates CS1 and CS014. An example of a new possibility is to prevent the progression of atrial fibrillation. One such expansion of indication could result in a significantly larger market potential than the company has previously communicated. Fibrosis is a fundamental mechanism for impaired...